article thumbnail

CMS proposes to Withdraw Trump Era Most Favored Nation (MFN) Drug Pricing Rule

FDA Law

The idea of basing Medicare drug reimbursement on prices in foreign countries was first proposed during the Obama Administration in 2016. Use of international reference pricing as a target for Medicare to negotiate prices with drug manufacturers appears in H.R. The Trump Administration rule had a troubled history. 3 , the “Elijah E.

Finance 52
article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.